Bayer Will Submit More Data To FDA On Aspirin MI Prevention Labeling
This article was originally published in The Tan Sheet
Executive Summary
Bayer will submit additional data on subpopulation risks associated with aspirin therapy to support its citizen petition requesting amended professional labeling for primary prevention of myocardial infarction